DK3056568T3
(da)
|
2006-03-31 |
2021-11-01 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
|
PL2173379T3
(pl)
|
2007-07-02 |
2016-02-29 |
Oncomed Pharm Inc |
Kompozycje oraz sposoby leczenia i diagnozowania nowotworu
|
MX336725B
(es)
|
2007-09-26 |
2016-01-28 |
Chugai Pharmaceutical Co Ltd |
Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
|
UA121453C2
(uk)
|
2008-04-11 |
2020-06-10 |
Чугей Сейяку Кабусікі Кайся |
Спосіб одержання фармацевтичної композиції, яка містить антитіло
|
JP6294585B2
(ja)
*
|
2009-09-03 |
2018-03-20 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
抗gitr抗体
|
TWI654204B
(zh)
|
2010-11-30 |
2019-03-21 |
中外製藥股份有限公司 |
具有鈣依存性的抗原結合能力之抗體
|
CN103842383B
(zh)
|
2011-05-16 |
2017-11-03 |
健能隆医药技术(上海)有限公司 |
多特异性fab融合蛋白及其使用方法
|
MX349198B
(es)
|
2011-07-15 |
2017-07-18 |
Oncomed Pharmaceuticals Inc * |
Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
|
US20130108641A1
(en)
*
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
KR101549637B1
(ko)
*
|
2012-06-08 |
2015-09-03 |
국립암센터 |
신규한 Th1 세포 전환용 에피토프 및 이의 용도
|
SG11201500233PA
(en)
|
2012-07-13 |
2015-04-29 |
Oncomed Pharm Inc |
Rspo3 binding agents and uses thereof
|
TWI855488B
(zh)
|
2012-08-24 |
2024-09-11 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
JP6774164B2
(ja)
|
2012-08-24 |
2020-10-21 |
中外製薬株式会社 |
マウスFcγRII特異的Fc抗体
|
US10548957B2
(en)
|
2012-09-28 |
2020-02-04 |
Dana-Farber Cancer Institute, Inc. |
Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritis
|
EP3508215A3
(en)
|
2012-12-03 |
2019-10-02 |
Bristol-Myers Squibb Company |
Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
|
EP2951199A4
(en)
|
2013-01-31 |
2016-07-20 |
Univ Jefferson |
Fusion proteins for the modulation of regulatory and effector T cells
|
WO2015116178A1
(en)
*
|
2014-01-31 |
2015-08-06 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector t cells
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
BR112015024587B1
(pt)
|
2013-04-02 |
2022-11-29 |
Chugai Seiyaku Kabushiki Kaisha |
Variante de região fc de igg1 humana, polipeptídeo compreendendo a mesma, seu método de produção e composição farmacêutica
|
CN105612175B
(zh)
|
2013-08-08 |
2023-05-09 |
赛腾制药 |
基于IL-15和IL-15Rαsushi结构域的调节因子
|
AR097306A1
(es)
*
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
TW201605896A
(zh)
*
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
EP4331605A3
(en)
|
2013-09-13 |
2024-05-22 |
F. Hoffmann-La Roche AG |
Methods and compositions comprising purified recombinant polypeptides
|
ES2915378T3
(es)
|
2013-09-13 |
2022-06-22 |
Hoffmann La Roche |
Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
|
WO2015066413A1
(en)
|
2013-11-01 |
2015-05-07 |
Novartis Ag |
Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
|
KR20160084438A
(ko)
|
2013-11-13 |
2016-07-13 |
노파르티스 아게 |
면역 반응을 강화하기 위한 mTOR 억제제
|
JP6779785B2
(ja)
|
2013-12-19 |
2020-11-04 |
ノバルティス アーゲー |
ヒトメソテリンキメラ抗原受容体およびその使用
|
SG11201605097SA
(en)
|
2013-12-24 |
2016-07-28 |
Bristol Myers Squibb Co |
Tricyclic compounds as anticancer agents
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
EA201691765A1
(ru)
|
2014-03-14 |
2016-12-30 |
Новартис Аг |
Молекулы антител против lag-3 и их применения
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
EA030850B1
(ru)
|
2014-03-24 |
2018-10-31 |
Новартис Аг |
Органические соединения, являющиеся монобактамами, для лечения бактериальных инфекций
|
LT3129470T
(lt)
|
2014-04-07 |
2021-07-12 |
Novartis Ag |
Vėžio gydymas naudojant anti-cd19 chimerinį antigeno receptorių
|
KR20220116578A
(ko)
|
2014-05-28 |
2022-08-23 |
아게누스 인코포레이티드 |
항-gitr 항체 및 이의 사용 방법
|
JP2017525753A
(ja)
|
2014-06-06 |
2017-09-07 |
フレクサス・バイオサイエンシーズ・インコーポレイテッドFlexus Biosciences, Inc. |
免疫調節剤
|
KR102204937B1
(ko)
|
2014-06-06 |
2021-01-18 |
브리스톨-마이어스 스큅 컴퍼니 |
글루코코르티코이드-유도 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
WO2016014565A2
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
BR112017001242A2
(pt)
|
2014-07-21 |
2017-12-05 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico a cd33
|
EP3660042B1
(en)
|
2014-07-31 |
2023-01-11 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
WO2016020836A1
(en)
|
2014-08-06 |
2016-02-11 |
Novartis Ag |
Quinolone derivatives as antibacterials
|
EP3180359A1
(en)
|
2014-08-14 |
2017-06-21 |
Novartis AG |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
MA40363A
(fr)
*
|
2014-08-15 |
2017-06-21 |
Oncomed Pharm Inc |
Agents de liaison de rspo1 et leurs utilisations
|
EP3183268B1
(en)
|
2014-08-19 |
2020-02-12 |
Novartis AG |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
CA2957958C
(en)
|
2014-08-27 |
2023-10-17 |
Harvey Cantor |
Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
|
BR112017004826A2
(pt)
|
2014-09-13 |
2017-12-12 |
Novartis Ag |
terapias de combinação de inibidores de alk
|
TW201628648A
(zh)
|
2014-09-16 |
2016-08-16 |
安可美德藥物股份有限公司 |
纖維變性疾病之治療
|
KR20250067191A
(ko)
|
2014-09-17 |
2025-05-14 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
CN107106687A
(zh)
|
2014-10-03 |
2017-08-29 |
诺华股份有限公司 |
组合治疗
|
MX2017004311A
(es)
|
2014-10-03 |
2017-12-07 |
Dana Farber Cancer Inst Inc |
Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
|
MA41044A
(fr)
*
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
CN106973568B
(zh)
|
2014-10-08 |
2021-07-23 |
诺华股份有限公司 |
预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
|
KR102513870B1
(ko)
|
2014-10-14 |
2023-03-23 |
노파르티스 아게 |
Pd-l1에 대한 항체 분자 및 그의 용도
|
KR20250009586A
(ko)
|
2014-10-29 |
2025-01-17 |
바이시클러드 리미티드 |
Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
|
UY36390A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
WO2016073738A2
(en)
|
2014-11-05 |
2016-05-12 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
AR102537A1
(es)
|
2014-11-05 |
2017-03-08 |
Flexus Biosciences Inc |
Agentes inmunomoduladores
|
US10653791B2
(en)
|
2014-11-21 |
2020-05-19 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
TWI711630B
(zh)
|
2014-11-21 |
2020-12-01 |
美商必治妥美雅史谷比公司 |
抗cd73抗體及其用途
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
RS59507B1
(sr)
|
2014-12-16 |
2019-12-31 |
Novartis Ag |
Jedinjenja izoksazol hidroksamske kiseline kao inhibitori lpxc
|
MX2017005774A
(es)
|
2014-12-19 |
2017-07-28 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
AR103232A1
(es)
|
2014-12-22 |
2017-04-26 |
Bristol Myers Squibb Co |
ANTAGONISTAS DE TGFbR
|
KR102644115B1
(ko)
|
2014-12-23 |
2024-03-05 |
브리스톨-마이어스 스큅 컴퍼니 |
Tigit에 대한 항체
|
KR102805767B1
(ko)
|
2014-12-29 |
2025-05-14 |
노파르티스 아게 |
키메라 항원 수용체-발현 세포를 제조하는 방법
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
EP3816179A3
(en)
|
2015-02-05 |
2021-08-04 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant comprising a modified fcrn-binding domain
|
AR103726A1
(es)
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
Cristales de anticuerpos monoclonales anti-pd-1 humanos
|
PE20171789A1
(es)
|
2015-03-02 |
2017-12-28 |
Bristol Myers Squibb Co |
Inhibidores del factor beta de crecimiento de transformacion (tgf-beta)
|
BR112017018908A2
(pt)
|
2015-03-10 |
2018-04-17 |
Aduro Biotech, Inc. |
composições e métodos para ativar a sinalização dependente do "estimulador do gene de interferon
|
EP3277670A1
(en)
|
2015-04-03 |
2018-02-07 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
|
ES2876974T3
(es)
|
2015-04-07 |
2021-11-15 |
Novartis Ag |
Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
|
TW201642897A
(zh)
|
2015-04-08 |
2016-12-16 |
F 星生物科技有限公司 |
Her2結合劑治療
|
EP4056588B1
(en)
|
2015-04-08 |
2024-09-25 |
Novartis AG |
Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
|
HUE053903T2
(hu)
|
2015-04-13 |
2021-07-28 |
Five Prime Therapeutics Inc |
Kombinációs terápia rák ellen
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
JP7114457B2
(ja)
|
2015-04-17 |
2022-08-08 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法
|
CN107743401B
(zh)
|
2015-04-17 |
2021-08-24 |
百时美施贵宝公司 |
包含抗pd-1抗体和另外的抗体的组合的组合物
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
WO2016183114A1
(en)
|
2015-05-11 |
2016-11-17 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
US9725449B2
(en)
|
2015-05-12 |
2017-08-08 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
SG10202002131PA
(en)
|
2015-05-21 |
2020-05-28 |
Harpoon Therapeutics Inc |
Trispecific binding proteins and methods of use
|
EP3302548A4
(en)
*
|
2015-06-03 |
2019-01-02 |
Dana Farber Cancer Institute, Inc. |
Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
|
CN107743586B
(zh)
|
2015-06-03 |
2021-07-02 |
百时美施贵宝公司 |
用于癌症诊断的抗gitr抗体
|
JP2018526977A
(ja)
|
2015-06-29 |
2018-09-20 |
ザ ロックフェラー ユニヴァーシティ |
アゴニスト活性が増強されたcd40に対する抗体
|
EP3943098A3
(en)
|
2015-07-16 |
2022-05-11 |
Biokine Therapeutics Ltd. |
Compositions and methods for treating cancer
|
CN109476722A
(zh)
|
2015-07-21 |
2019-03-15 |
诺华股份有限公司 |
用于改善免疫细胞的功效和扩张的方法
|
US10093742B2
(en)
|
2015-07-23 |
2018-10-09 |
Inhibrx, Inc. |
Multispecific GITR-binding fusion proteins and methods of use thereof
|
KR20180034548A
(ko)
|
2015-07-28 |
2018-04-04 |
브리스톨-마이어스 스큅 컴퍼니 |
Tgf 베타 수용체 길항제
|
SI3317301T1
(sl)
|
2015-07-29 |
2021-10-29 |
Novartis Ag |
Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
|
EP3316902A1
(en)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
JP6878405B2
(ja)
|
2015-07-29 |
2021-05-26 |
ノバルティス アーゲー |
Pd−1に対する抗体分子を含む組み合わせ治療
|
JP2018525415A
(ja)
|
2015-08-25 |
2018-09-06 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Tgfベータ受容体アンタゴニスト
|
JP6905163B2
(ja)
|
2015-09-03 |
2021-07-21 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
サイトカイン放出症候群を予測するバイオマーカー
|
US20190022092A1
(en)
|
2015-09-15 |
2019-01-24 |
Acerta Pharma B.V. |
Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
|
AU2016341403B2
(en)
*
|
2015-10-22 |
2023-08-03 |
Ablynx Nv |
GITR agonists
|
CN108884139A
(zh)
|
2015-11-02 |
2018-11-23 |
戊瑞治疗有限公司 |
Cd80胞外域多肽及其在癌症治疗中的用途
|
CA3004117A1
(en)
|
2015-11-03 |
2017-05-11 |
Janssen Biotech, Inc. |
Antibodies specifically binding pd-1 and their uses
|
EA201891121A1
(ru)
|
2015-11-19 |
2018-12-28 |
Бристол-Майерс Сквибб Компани |
Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения
|
AU2016359609B2
(en)
|
2015-11-23 |
2023-12-07 |
Five Prime Therapeutics, Inc. |
FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
|
CA3007233A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Antibodies and methods of use thereof
|
EP3390406A1
(en)
|
2015-12-15 |
2018-10-24 |
Bristol-Myers Squibb Company |
Cxcr4 receptor antagonists
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
HK1258204A1
(zh)
|
2015-12-18 |
2019-11-08 |
Novartis Ag |
靶向cd32b的抗体及其使用方法
|
JP7082055B2
(ja)
|
2015-12-22 |
2022-06-07 |
ノバルティス アーゲー |
抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体(car)およびpd-l1阻害剤に対する抗体
|
US11359009B2
(en)
|
2015-12-25 |
2022-06-14 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
JP2019500874A
(ja)
|
2015-12-28 |
2019-01-17 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞の作製方法
|
JP6993699B2
(ja)
|
2016-01-11 |
2022-02-03 |
ウニヴェルズィテート・ツューリヒ |
ヒトインターロイキン-2に対する免疫刺激性ヒト化モノクローナル抗体及びその融合タンパク質
|
US20200270265A1
(en)
|
2016-02-19 |
2020-08-27 |
Novartis Ag |
Tetracyclic pyridone compounds as antivirals
|
SG10201913033UA
(en)
|
2016-03-04 |
2020-03-30 |
Bristol Myers Squibb Co |
Combination therapy with anti-cd73 antibodies
|
KR20180118175A
(ko)
|
2016-03-04 |
2018-10-30 |
노파르티스 아게 |
다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
|
CA3016894A1
(en)
*
|
2016-03-08 |
2017-09-14 |
Janssen Biotech, Inc. |
Gitr antibodies, methods, and uses
|
AU2017233121B2
(en)
|
2016-03-15 |
2023-12-21 |
Itabmed (Hk) Limited |
Multispecific Fab fusion proteins and use thereof
|
ES2962269T3
(es)
|
2016-03-24 |
2024-03-18 |
Novartis Ag |
Análogos de nucleósidos alquinil como inhibidores del rinovirus humano
|
EP3432927A4
(en)
|
2016-03-24 |
2019-11-20 |
Gensun Biopharma Inc. |
TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT
|
AU2017250191A1
(en)
|
2016-04-13 |
2018-11-08 |
Orimabs Ltd. |
Anti-PSMA antibodies and use thereof
|
EP3452452A4
(en)
|
2016-05-04 |
2019-10-30 |
Bristol-Myers Squibb Company |
INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE AND METHOD FOR THEIR USE
|
WO2017192811A1
(en)
|
2016-05-04 |
2017-11-09 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
WO2017192813A1
(en)
|
2016-05-04 |
2017-11-09 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
KR20190003687A
(ko)
|
2016-05-04 |
2019-01-09 |
브리스톨-마이어스 스큅 컴퍼니 |
인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
|
US10544099B2
(en)
|
2016-05-04 |
2020-01-28 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
TWI755395B
(zh)
|
2016-05-13 |
2022-02-21 |
美商再生元醫藥公司 |
抗-pd-1抗體與輻射治療癌症之組合
|
SG11201809669RA
(en)
|
2016-05-20 |
2018-11-29 |
Biohaven Pharm Holding Co Ltd |
Use of glutamate modulating agents with immunotherapies to treat cancer
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
SG11201810525XA
(en)
|
2016-06-10 |
2018-12-28 |
Regeneron Pharma |
Anti-gitr antibodies and uses thereof
|
WO2017216705A1
(en)
|
2016-06-14 |
2017-12-21 |
Novartis Ag |
Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
SG11201810509PA
(en)
|
2016-06-20 |
2018-12-28 |
Kymab Ltd |
Anti-pd-l1 antibodies
|
BR112018077021A2
(pt)
|
2016-06-24 |
2019-04-02 |
Infinity Pharmaceuticals, Inc. |
terapias de combinação
|
CN109641967A
(zh)
|
2016-07-01 |
2019-04-16 |
戊瑞治疗有限公司 |
用GITR激动剂和CpG的组合的抗肿瘤疗法
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
CA3030765A1
(en)
|
2016-07-14 |
2018-01-18 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
EP3487878A4
(en)
|
2016-07-20 |
2020-03-25 |
University of Utah Research Foundation |
CAR-T CD229 LYMPHOCYTES AND METHODS OF USE
|
WO2018017633A1
(en)
|
2016-07-21 |
2018-01-25 |
Bristol-Myers Squibb Company |
TGF Beta RECEPTOR ANTAGONISTS
|
WO2018018039A2
(en)
*
|
2016-07-22 |
2018-01-25 |
Dana-Farber Cancer Institute, Inc. |
Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
|
KR102102734B1
(ko)
|
2016-08-05 |
2020-04-22 |
추가이 세이야쿠 가부시키가이샤 |
Il-8 관련 질환의 치료용 또는 예방용 조성물
|
KR102587941B1
(ko)
|
2016-08-12 |
2023-10-11 |
얀센 바이오테크 인코포레이티드 |
향상된 효능작용 및 이펙터 기능을 갖는 조작된 항체 및 다른 Fc-도메인 함유 분자
|
SG11201900744SA
(en)
|
2016-08-12 |
2019-02-27 |
Janssen Biotech Inc |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
JP2019528300A
(ja)
|
2016-08-26 |
2019-10-10 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
インドールアミン2,3−ジオキシゲナーゼの阻害剤およびその使用方法
|
TW201811788A
(zh)
|
2016-09-09 |
2018-04-01 |
瑞士商諾華公司 |
作為抗病毒劑之多環吡啶酮化合物
|
WO2018057585A1
(en)
|
2016-09-21 |
2018-03-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
|
JOP20190061A1
(ar)
|
2016-09-28 |
2019-03-26 |
Novartis Ag |
مثبطات بيتا-لاكتاماز
|
MY200337A
(en)
|
2016-10-07 |
2023-12-20 |
Novartis Ag |
Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
|
EA037973B1
(ru)
*
|
2016-10-12 |
2021-06-18 |
Янссен Байотек, Инк. |
Антитела к gitr, способы и применение
|
WO2018073753A1
(en)
|
2016-10-18 |
2018-04-26 |
Novartis Ag |
Fused tetracyclic pyridone compounds as antivirals
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
AU2017359467A1
(en)
|
2016-11-09 |
2019-05-02 |
Agenus Inc. |
Anti-OX40 antibodies, anti-GITR antibodies, and methods of use thereof
|
US10660909B2
(en)
|
2016-11-17 |
2020-05-26 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
US20200078400A1
(en)
|
2016-12-03 |
2020-03-12 |
Juno Therapeutics, Inc. |
Methods for determining car-t cells dosing
|
WO2018115485A1
(en)
|
2016-12-22 |
2018-06-28 |
Pierfrancesco Tassone |
A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
|
JOP20190154B1
(ar)
|
2016-12-22 |
2022-09-15 |
Amgen Inc |
بنز أيزو ثيازول، أيزو ثيازولو [3، 4-b] بيريدين، كينازولين، فثالازين، بيريدو [2، 3-d] بيريدازين ومشتقات بيريدو [2، 3-d] بيريميدين على هيئة مثبطات kras g12c لمعالجة سرطان الرئة، أو سرطان البنكرياس أو سرطان القولون والمستقيم
|
WO2018132279A1
(en)
|
2017-01-05 |
2018-07-19 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
WO2018128939A1
(en)
|
2017-01-05 |
2018-07-12 |
Gensun Biopharma Inc. |
Checkpoint regulator antagonists
|
BR112019013940A2
(pt)
|
2017-01-06 |
2020-02-11 |
Iovance Biotherapeutics, Inc. |
Método de tratar um câncer com uma população de linfócitos infiltrantes de tumor, processo para preparação de uma população de linfócitos infiltrantes de tumor, população de linfócitos infiltrantes de tumor, e, composição farmacêutica.
|
KR102611446B1
(ko)
|
2017-01-20 |
2023-12-06 |
아르커스 바이오사이언시즈 인코포레이티드 |
암-관련 장애의 치료를 위한 아졸로피리미딘
|
BR112019015453A2
(pt)
*
|
2017-01-27 |
2020-03-24 |
Ultrahuman One Limited |
Agentes ligantes
|
CA3052740A1
(en)
*
|
2017-02-10 |
2018-08-16 |
Eutilex Co., Ltd. |
Ifn-.gamma.-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof
|
IL321717A
(en)
|
2017-02-21 |
2025-08-01 |
Regeneron Pharma |
Anti-PD-1 antibodies for the treatment of lung cancer
|
CN110431152A
(zh)
*
|
2017-03-03 |
2019-11-08 |
雷纳神经科学公司 |
抗gitr抗体及其使用方法
|
JP7458188B2
(ja)
|
2017-03-31 |
2024-03-29 |
ブリストル-マイヤーズ スクイブ カンパニー |
腫瘍を処置する方法
|
JP2020515637A
(ja)
|
2017-04-03 |
2020-05-28 |
オンコロジー、インコーポレイテッド |
免疫腫瘍剤を伴うps標的化抗体を用いる癌の治療方法
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
WO2018193102A1
(en)
|
2017-04-20 |
2018-10-25 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
EP3612236A1
(en)
|
2017-04-20 |
2020-02-26 |
ADC Therapeutics SA |
Combination therapy with an anti-cd25 antibody-drug conjugate
|
TWI778050B
(zh)
|
2017-04-21 |
2022-09-21 |
美商醫肯納腫瘤學公司 |
吲哚ahr抑制劑及其用途
|
CN110621341A
(zh)
|
2017-04-26 |
2019-12-27 |
百时美施贵宝公司 |
使二硫键还原最小化的抗体生产方法
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
AU2018258661A1
(en)
|
2017-04-28 |
2019-10-17 |
Five Prime Therapeutics, Inc. |
Methods of treatment with CD80 extracellular domain polypeptides
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
KR20200003107A
(ko)
|
2017-05-02 |
2020-01-08 |
머크 샤프 앤드 돔 코포레이션 |
항-lag3 항체의 제제, 및 항-lag3 항체 및 항-pd-1 항체의 공동-제제
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
EA039583B1
(ru)
*
|
2017-05-02 |
2022-02-14 |
Регенерон Фармасьютикалз, Инк. |
Антитела против gitr и их применения
|
AR111658A1
(es)
|
2017-05-05 |
2019-08-07 |
Novartis Ag |
2-quinolinonas tricíclicas como agentes antibacteriales
|
SG10202107880XA
(en)
|
2017-05-12 |
2021-09-29 |
Harpoon Therapeutics Inc |
Mesothelin binding proteins
|
US11066392B2
(en)
|
2017-05-12 |
2021-07-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US11685787B2
(en)
|
2017-05-16 |
2023-06-27 |
Bristol-Myers Squibb Company |
Treatment of cancer with anti-GITR agonist antibodies
|
US11220492B2
(en)
|
2017-05-17 |
2022-01-11 |
Arcus Biosciences, Inc. |
Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
EP3630833A1
(en)
|
2017-05-25 |
2020-04-08 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
AU2018275109A1
(en)
|
2017-06-01 |
2020-01-02 |
Xencor, Inc. |
Bispecific antibodies that bind CD 123 CD3
|
WO2018223004A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
JP2020522489A
(ja)
|
2017-06-02 |
2020-07-30 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法を用いる処置のための製造物品および方法
|
AU2018281830B2
(en)
|
2017-06-09 |
2023-11-02 |
Agonox, Inc. |
Utilization of CD39 and CD103 for identification of human tumor reactive cells for treatment of cancer
|
UA127900C2
(uk)
|
2017-06-14 |
2024-02-07 |
Ейдісі Терапьютікс Са |
Схема дозування для введення adc до cd19
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
CN109136275B
(zh)
|
2017-06-19 |
2021-03-16 |
百奥赛图(北京)医药科技股份有限公司 |
人源化gitr基因改造动物模型的制备方法及应用
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
AU2018287519B2
(en)
|
2017-06-22 |
2021-07-22 |
Novartis Ag |
IL-1beta binding antibodies for use in treating cancer
|
CU24606B1
(es)
|
2017-06-22 |
2022-06-06 |
Novartis Ag |
Moléculas de anticuerpo que se unen a cd73
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
US20200223924A1
(en)
|
2017-06-27 |
2020-07-16 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
AU2018291032A1
(en)
|
2017-06-29 |
2020-01-16 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
EP3647323A4
(en)
*
|
2017-06-30 |
2021-10-27 |
Jiangsu Hengrui Medicine Co., Ltd. |
ANTI-GITR ANTIBODIES, ANTIGEN BINDING FRAGMENT AND ASSOCIATED PHARMACEUTICAL USE
|
AU2018294314B2
(en)
|
2017-06-30 |
2024-09-19 |
Bristol-Myers Squibb Company |
Amorphous and crystalline forms of IDO inhibitors
|
CN111163798A
(zh)
|
2017-07-20 |
2020-05-15 |
诺华股份有限公司 |
用于抗lag-3抗体的给药方案及其用途
|
ES2932354T3
(es)
|
2017-07-28 |
2023-01-18 |
Bristol Myers Squibb Co |
Dinucleótidos cíclicos como agentes anticáncer
|
US11261214B2
(en)
|
2017-08-04 |
2022-03-01 |
Bicycletx Limited |
Bicyclic peptide ligand specific for CD137
|
BR112020003116A2
(pt)
|
2017-08-17 |
2020-08-04 |
Ikena Oncology, Inc. |
inibidores de ahr e usos dos mesmos
|
PE20200797A1
(es)
|
2017-08-25 |
2020-08-10 |
Five Prime Therapeutics Inc |
Anticuerpos que se unen especificamente a b7-h4 humana
|
US10947263B2
(en)
|
2017-08-31 |
2021-03-16 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
KR102812783B1
(ko)
|
2017-08-31 |
2025-05-26 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
JP7208225B2
(ja)
|
2017-08-31 |
2023-01-18 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗癌剤としての環状ジヌクレオチド
|
AR112797A1
(es)
|
2017-09-08 |
2019-12-11 |
Amgen Inc |
Inhibidores de kras g12c y métodos para utilizarlos
|
JP7366031B2
(ja)
|
2017-09-22 |
2023-10-20 |
カイメラ セラピューティクス, インコーポレイテッド |
タンパク質分解剤およびそれらの使用
|
EP3684366A4
(en)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES OF THE LATEST
|
US11649212B2
(en)
|
2017-10-09 |
2023-05-16 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US11203592B2
(en)
|
2017-10-09 |
2021-12-21 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
EP3694867A1
(en)
|
2017-10-10 |
2020-08-19 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
KR102569133B1
(ko)
|
2017-10-13 |
2023-08-21 |
하푼 테라퓨틱스, 인크. |
삼중특이적 단백질 및 사용 방법
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
US20200239577A1
(en)
|
2017-10-15 |
2020-07-30 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
CN111406063B
(zh)
|
2017-10-16 |
2023-09-15 |
百时美施贵宝公司 |
作为抗癌剂的环二核苷酸
|
EP3700933A1
(en)
|
2017-10-25 |
2020-09-02 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
CA3078270A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
AU2018358067A1
(en)
|
2017-11-01 |
2020-05-07 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
|
US12031975B2
(en)
|
2017-11-01 |
2024-07-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
CN111902159A
(zh)
|
2017-11-01 |
2020-11-06 |
朱诺治疗学股份有限公司 |
对b细胞成熟抗原(bcma)具有特异性的嵌合抗原受体
|
US11166959B2
(en)
|
2017-11-06 |
2021-11-09 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as HPK1 inhibitors
|
WO2019099838A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
WO2019097479A1
(en)
|
2017-11-17 |
2019-05-23 |
Novartis Ag |
Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
|
EP3716980A1
(en)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics, Inc. |
Methods for dosing and for modulation of genetically engineered cells
|
CN112204048A
(zh)
|
2017-12-15 |
2021-01-08 |
朱诺治疗学股份有限公司 |
抗cct5结合分子及其使用方法
|
JP2021507906A
(ja)
|
2017-12-20 |
2021-02-25 |
ノバルティス アーゲー |
抗ウイルス剤としての融合三環式ピラゾロ−ジヒドロピラジニル−ピリドン化合物
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
US11306149B2
(en)
|
2017-12-27 |
2022-04-19 |
Bristol-Myers Squibb Company |
Anti-CD40 antibodies and uses thereof
|
WO2019136112A1
(en)
|
2018-01-05 |
2019-07-11 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
|
US12129297B2
(en)
|
2018-01-12 |
2024-10-29 |
Bristol-Myers Squibb Company |
Antibodies against TIM3 and uses thereof
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
JP7377207B2
(ja)
|
2018-01-29 |
2023-11-09 |
メルク パテント ゲーエムベーハー |
Gcn2阻害剤およびその使用
|
WO2019148132A1
(en)
|
2018-01-29 |
2019-08-01 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
WO2019160829A1
(en)
|
2018-02-13 |
2019-08-22 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
US10519187B2
(en)
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
AU2019224659A1
(en)
|
2018-02-23 |
2020-10-15 |
Bicycletx Limited |
Multimeric bicyclic peptide ligands
|
WO2019165315A1
(en)
|
2018-02-23 |
2019-08-29 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists alone or in combination
|
JP2021514982A
(ja)
|
2018-02-28 |
2021-06-17 |
ノバルティス アーゲー |
インドール−2−カルボニル化合物及びb型肝炎治療のためのそれらの使用
|
CN111971308A
(zh)
|
2018-03-02 |
2020-11-20 |
戊瑞治疗有限公司 |
B7-h4抗体及其使用方法
|
CN111818928A
(zh)
|
2018-03-05 |
2020-10-23 |
艾库斯生物科学有限公司 |
精氨酸酶抑制剂
|
US11945834B2
(en)
|
2018-03-08 |
2024-04-02 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
PE20210290A1
(es)
|
2018-03-21 |
2021-02-11 |
Five Prime Therapeutics Inc |
ANTICUERPOS DE UNION A VISTA A pH ACIDO
|
CA3093407A1
(en)
|
2018-03-23 |
2019-09-26 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
CN110357958A
(zh)
|
2018-03-26 |
2019-10-22 |
信达生物制药(苏州)有限公司 |
抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)的小型化抗体、其聚合物及应用
|
WO2019184909A1
(zh)
|
2018-03-27 |
2019-10-03 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
US20210024873A1
(en)
|
2018-03-27 |
2021-01-28 |
Bristol-Myers Squibb Company |
Real-time monitoring of protein concentration using ultraviolet signal
|
CN110305210B
(zh)
|
2018-03-27 |
2023-02-28 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
JP2021519771A
(ja)
|
2018-03-30 |
2021-08-12 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
腫瘍を処置する方法
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
US10973834B2
(en)
|
2018-04-16 |
2021-04-13 |
Arrys Therapeutics, Inc. |
EP4 inhibitors and use thereof
|
CN110386981A
(zh)
*
|
2018-04-20 |
2019-10-29 |
信达生物制药(苏州)有限公司 |
抗gitr抗体及其用途
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
WO2019213340A1
(en)
|
2018-05-03 |
2019-11-07 |
Bristol-Myers Squibb Company |
Uracil derivatives as mer-axl inhibitors
|
MX2020011582A
(es)
|
2018-05-04 |
2020-11-24 |
Amgen Inc |
Inhibidores de kras g12c y metodos para su uso.
|
JP7266043B2
(ja)
|
2018-05-04 |
2023-04-27 |
アムジエン・インコーポレーテツド |
KRas G12C阻害剤及びそれを使用する方法
|
WO2019217691A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
EP3796942A1
(en)
|
2018-05-23 |
2021-03-31 |
ADC Therapeutics SA |
Molecular adjuvant
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
WO2019232419A1
(en)
|
2018-06-01 |
2019-12-05 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
US20210205449A1
(en)
|
2018-06-01 |
2021-07-08 |
Novartis Ag |
Dosing of a bispecific antibody that bind cd123 and cd3
|
MX2020012204A
(es)
|
2018-06-11 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c para tratar el cáncer.
|
US11285156B2
(en)
|
2018-06-12 |
2022-03-29 |
Amgen Inc. |
Substituted piperazines as KRAS G12C inhibitors
|
MY208825A
(en)
|
2018-06-13 |
2025-05-30 |
Novartis Ag |
Bcma chimeric antigen receptors and uses thereof
|
CA3103629A1
(en)
|
2018-06-15 |
2019-12-19 |
Flagship Pioneering Innovations V, Inc. |
Increasing immune activity through modulation of postcellular signaling factors
|
IL279489B1
(en)
|
2018-06-22 |
2025-06-01 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for nectin-4, a drug conjugate comprising the peptide ligand and a pharmaceutical composition comprising the drug conjugate
|
HUE064531T2
(hu)
|
2018-06-27 |
2024-04-28 |
Bristol Myers Squibb Co |
Szubsztituált naftiridinon vegyületek mint T-sejt aktivátorok
|
CN112585139B
(zh)
|
2018-06-27 |
2023-12-01 |
百时美施贵宝公司 |
用作t细胞激活剂的萘啶酮化合物
|
EP3813864A4
(en)
|
2018-06-29 |
2022-07-20 |
Gensun Biopharma Inc. |
Antitumor antagonists
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
PE20211604A1
(es)
|
2018-07-09 |
2021-08-23 |
Five Prime Therapeutics Inc |
Anticuerpos de union a ilt4
|
AU2019301944B2
(en)
|
2018-07-10 |
2022-02-24 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
AU2019301120A1
(en)
|
2018-07-11 |
2021-02-25 |
Bristol-Myers Squibb Company |
Antibodies binding to VISTA at acidic pH
|
EP3823614A4
(en)
|
2018-07-18 |
2022-03-30 |
Arcus Biosciences, Inc. |
SOLID FORMS OF AN AZOLOPYRIMIDINE COMPOUND
|
US12145927B2
(en)
|
2018-07-23 |
2024-11-19 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US12059420B2
(en)
|
2018-07-23 |
2024-08-13 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US12195533B2
(en)
|
2018-07-24 |
2025-01-14 |
Inhibrx Biosciences, Inc. |
Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
ES2982326T3
(es)
|
2018-07-27 |
2024-10-15 |
Arcus Biosciences Inc |
Antagonistas de la piridona A2R
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
CA3109959A1
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
WO2020047449A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
AU2019336197A1
(en)
|
2018-09-07 |
2021-02-18 |
Pfizer Inc. |
Anti-avb8 antibodies and compositions and uses thereof
|
US12030875B2
(en)
|
2018-09-07 |
2024-07-09 |
PIC Therapeutics, Inc. |
EIF4E inhibitors and uses thereof
|
WO2020053654A1
(en)
|
2018-09-12 |
2020-03-19 |
Novartis Ag |
Antiviral pyridopyrazinedione compounds
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
AU2019346466A1
(en)
|
2018-09-25 |
2021-05-20 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
WO2020069405A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
WO2020069409A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
EP3856345A1
(en)
|
2018-09-29 |
2021-08-04 |
Novartis AG |
Process of manufacture of a compound for inhibiting the activity of shp2
|
WO2020077257A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Pd-1 single domain antibodies and therapeutic compositions thereof
|
CN113166263A
(zh)
|
2018-10-11 |
2021-07-23 |
印希比股份有限公司 |
Dll3单域抗体及其治疗性组合物
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
CA3117419A1
(en)
|
2018-11-01 |
2020-05-07 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
CN119569895A
(zh)
|
2018-11-01 |
2025-03-07 |
朱诺治疗学股份有限公司 |
G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体
|
CA3118144A1
(en)
|
2018-11-07 |
2020-05-14 |
Merck Sharp & Dohme Corp. |
Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
|
KR20210092769A
(ko)
|
2018-11-16 |
2021-07-26 |
브리스톨-마이어스 스큅 컴퍼니 |
항-nkg2a 항체 및 그의 용도
|
AR117102A1
(es)
|
2018-11-16 |
2021-07-14 |
Arcus Biosciences Inc |
Inhibidores de arg1 y/o arg2
|
US20220008465A1
(en)
|
2018-11-16 |
2022-01-13 |
Juno Therapeutics, Inc. |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
US11053226B2
(en)
|
2018-11-19 |
2021-07-06 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
KR20210096167A
(ko)
|
2018-11-28 |
2021-08-04 |
브리스톨-마이어스 스큅 컴퍼니 |
변형된 중쇄 불변 영역을 포함하는 항체
|
ES2981569T3
(es)
|
2018-11-30 |
2024-10-09 |
Juno Therapeutics Inc |
Métodos de tratamiento usando terapia celular adoptiva
|
WO2020113233A1
(en)
|
2018-11-30 |
2020-06-04 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
US20240245670A1
(en)
|
2018-12-20 |
2024-07-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
AU2019404576B2
(en)
|
2018-12-20 |
2025-07-17 |
Amgen Inc. |
Heteroaryl amides useful as KIF18A inhibitors
|
IL283639B2
(en)
|
2018-12-20 |
2024-06-01 |
Amgen Inc |
Kif18a inhibitors
|
CA3123042A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
CA3123044A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
WO2020128613A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1beta binding antibodies
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
KR20210107730A
(ko)
|
2018-12-21 |
2021-09-01 |
노파르티스 아게 |
골수 형성이상 증후군의 치료 또는 예방에서의 il-1 베타 항체의 용도
|
US20220056123A1
(en)
|
2018-12-21 |
2022-02-24 |
Novartis Ag |
Use of il-1beta binding antibodies
|
EA202192103A1
(ru)
|
2019-01-29 |
2021-12-15 |
Джуно Терапьютикс, Инк. |
Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1)
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
US20220144807A1
(en)
|
2019-02-15 |
2022-05-12 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
WO2020172658A1
(en)
|
2019-02-24 |
2020-08-27 |
Bristol-Myers Squibb Company |
Methods of isolating a protein
|
MX2021010319A
(es)
|
2019-03-01 |
2021-12-10 |
Revolution Medicines Inc |
Compuestos biciclicos de heteroarilo y usos de estos.
|
EP3930845A1
(en)
|
2019-03-01 |
2022-01-05 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
WO2020185859A1
(en)
|
2019-03-12 |
2020-09-17 |
Arcus Biosciences, Inc. |
Treatment of oncogene-driven cancers
|
EP3941503A1
(en)
|
2019-03-19 |
2022-01-26 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
|
WO2020205662A1
(en)
|
2019-03-29 |
2020-10-08 |
Myst Therapeutics, Inc. |
Ex vivo methods for producing a t cell therapeutic and related compositions and methods
|
EP3947463A4
(en)
|
2019-03-29 |
2022-12-21 |
Arcus Biosciences, Inc. |
CANCER TREATMENT USING AN IDENTIFIED ADENOSINE IMPRESSION
|
JP2022528887A
(ja)
|
2019-04-02 |
2022-06-16 |
バイスクルテクス・リミテッド |
バイシクルトキシンコンジュゲートおよびその使用
|
MA55565A
(fr)
|
2019-04-05 |
2022-02-09 |
Kymera Therapeutics Inc |
Agents de dégradation de stat et leurs utilisations
|
US20220168389A1
(en)
|
2019-04-12 |
2022-06-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
RU2734432C1
(ru)
|
2019-04-23 |
2020-10-16 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с GITR
|
WO2020219742A1
(en)
|
2019-04-24 |
2020-10-29 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
WO2020227159A2
(en)
|
2019-05-03 |
2020-11-12 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity
|
US20230295087A1
(en)
|
2019-05-13 |
2023-09-21 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
WO2020231713A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
UA129871C2
(uk)
|
2019-05-21 |
2025-08-27 |
Емджен Інк. |
Тверді форми
|
KR20220012292A
(ko)
|
2019-05-23 |
2022-02-03 |
브리스톨-마이어스 스큅 컴퍼니 |
세포 배양 배지를 모니터링하는 방법
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
WO2020243568A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
|
KR20220016157A
(ko)
|
2019-05-30 |
2022-02-08 |
브리스톨-마이어스 스큅 컴퍼니 |
세포 국재화 시그너쳐 및 조합 요법
|
BR112021024224A2
(pt)
|
2019-05-31 |
2022-04-26 |
Ikena Oncology Inc |
Inibidores de tead e usos dos mesmos
|
WO2020263312A1
(en)
|
2019-06-28 |
2020-12-30 |
Gensun Biopharma, Inc. |
ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
|
MX2022001295A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
EP4007756A1
(en)
|
2019-08-02 |
2022-06-08 |
Amgen Inc. |
Kif18a inhibitors
|
MX2022001296A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
EP4007638A1
(en)
|
2019-08-02 |
2022-06-08 |
Amgen Inc. |
Pyridine derivatives as kif18a inhibitors
|
US20220306630A1
(en)
|
2019-08-06 |
2022-09-29 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
US12215105B2
(en)
|
2019-09-13 |
2025-02-04 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
TW202124448A
(zh)
|
2019-09-19 |
2021-07-01 |
美商必治妥美雅史谷比公司 |
於酸性pH結合VISTA之抗體
|
CA3155287A1
(en)
|
2019-09-26 |
2021-04-01 |
Novartis Ag |
Antiviral pyrazolopyridinone compounds
|
MX2022004769A
(es)
|
2019-10-21 |
2022-05-16 |
Novartis Ag |
Inhibidores de tim-3 y sus usos.
|
BR112022007376A2
(pt)
|
2019-10-21 |
2022-07-05 |
Novartis Ag |
Terapias de combinação com venetoclax e inibidores de tim-3
|
US20240190862A1
(en)
|
2019-10-24 |
2024-06-13 |
Amgen Inc. |
Epoxyamides as kras g12c and kras g12d inhibitors and methods of using the same
|
CN115873020B
(zh)
|
2019-11-04 |
2025-06-13 |
锐新医药公司 |
Ras抑制剂
|
US11566007B2
(en)
|
2019-11-04 |
2023-01-31 |
Revolution Medicines, Inc. |
Ras inhibitors
|
AU2020377925A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
CN116425742A
(zh)
|
2019-11-08 |
2023-07-14 |
锐新医药公司 |
双环杂芳基化合物及其用途
|
CN120463705A
(zh)
|
2019-11-14 |
2025-08-12 |
美国安进公司 |
Kras g12c抑制剂化合物的改善的合成
|
MX2022005726A
(es)
|
2019-11-14 |
2022-06-09 |
Amgen Inc |
Sintesis mejorada del compuesto inhibidor de g12c de kras.
|
AU2020387392B2
(en)
|
2019-11-19 |
2025-09-11 |
Bristol-Myers Squibb Company |
Compounds useful as inhibitors of Helios protein
|
MX2022006391A
(es)
|
2019-11-26 |
2022-06-24 |
Novartis Ag |
Receptores de antigeno quimerico que se unen a bcma y cd19 y usos de los mismos.
|
CA3162892A1
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
JP2023504400A
(ja)
|
2019-11-26 |
2023-02-03 |
ブリストル-マイヤーズ スクイブ カンパニー |
(r)-n-(4-クロロフェニル)-2-((1s,4s)-4-(6-フルオロキノリン-4-イル)シクロヘキシル)プロパンアミドの塩/共結晶
|
FI4065582T3
(fi)
|
2019-11-26 |
2025-05-25 |
Ikena Oncology Inc |
Polymorfisia karbatsolijohdannaisia ja niiden käyttötapoja
|
GB201917254D0
(en)
|
2019-11-27 |
2020-01-08 |
Adc Therapeutics Sa |
Combination therapy
|
US20230032934A1
(en)
|
2019-11-27 |
2023-02-02 |
Myst Therapeutics, Llc |
Method of producing tumor-reactive t cell composition using modulatory agents
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
WO2021127217A1
(en)
|
2019-12-17 |
2021-06-24 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
PH12022551524A1
(en)
|
2019-12-17 |
2024-01-29 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
CN115175937A
(zh)
|
2019-12-20 |
2022-10-11 |
诺华股份有限公司 |
用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
|
BR112022012220A2
(pt)
|
2019-12-23 |
2022-09-13 |
Bristol Myers Squibb Co |
Compostos de piperazina quinolinonil substituída úteis como ativadores de célula t
|
CN115175907B
(zh)
|
2019-12-23 |
2024-08-02 |
百时美施贵宝公司 |
可用作t细胞激活剂的经取代的哌嗪衍生物
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos útiles como activadores de células t
|
AU2020412780A1
(en)
|
2019-12-23 |
2022-07-21 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
IL294273A
(en)
|
2019-12-23 |
2022-08-01 |
Bristol Myers Squibb Co |
Substituted heteroaryl compounds useful as t cell activators
|
CN114846007B
(zh)
|
2019-12-23 |
2024-11-22 |
百时美施贵宝公司 |
可用作t细胞激活剂的经取代的喹唑啉基化合物
|
EP4087874A1
(en)
|
2020-01-06 |
2022-11-16 |
HiFiBiO (HK) Limited |
Anti-tnfr2 antibody and uses thereof
|
JP7719799B2
(ja)
|
2020-01-07 |
2025-08-06 |
ハイファイバイオ, インコーポレイテッド |
抗ガレクチン-9抗体およびその使用
|
CA3163703A1
(en)
|
2020-01-07 |
2021-07-15 |
Steve Kelsey |
Shp2 inhibitor dosing and methods of treating cancer
|
US20230058489A1
(en)
|
2020-01-17 |
2023-02-23 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
WO2021163618A1
(en)
|
2020-02-14 |
2021-08-19 |
Novartis Ag |
Method of predicting response to chimeric antigen receptor therapy
|
MX2022010517A
(es)
|
2020-02-27 |
2022-11-14 |
Myst Therapeutics Llc |
Metodos para la expansion y enriquecimiento ex vivo de celulas t reactivas a tumor y composiciones relacionadas de las mismas.
|
CA3173737A1
(en)
|
2020-02-27 |
2021-09-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
WO2021171264A1
(en)
|
2020-02-28 |
2021-09-02 |
Novartis Ag |
Dosing of a bispecific antibody that binds cd123 and cd3
|
WO2021178488A1
(en)
|
2020-03-03 |
2021-09-10 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
AU2021232041A1
(en)
|
2020-03-06 |
2022-09-08 |
Regeneron Pharmaceuticals, Inc. |
Anti-GITR antibodies and uses thereof
|
JP2023516459A
(ja)
|
2020-03-09 |
2023-04-19 |
ブリストル-マイヤーズ スクイブ カンパニー |
増強されたアゴニスト活性を有するcd40に対する抗体
|
TW202200543A
(zh)
|
2020-03-19 |
2022-01-01 |
美商凱麥拉醫療公司 |
Mdm2降解劑及其用途
|
IL295569A
(en)
|
2020-03-19 |
2022-10-01 |
Arcus Biosciences Inc |
Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
CA3179800A1
(en)
|
2020-04-10 |
2021-10-14 |
Juno Therapeutics, Inc. |
Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
CA3176246A1
(en)
|
2020-06-02 |
2021-12-09 |
Arcus Biosciences, Inc. |
Antibodies to tigit
|
WO2021247897A1
(en)
|
2020-06-03 |
2021-12-09 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
CA3185455A1
(en)
|
2020-06-11 |
2021-12-16 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
JP2023530351A
(ja)
|
2020-06-18 |
2023-07-14 |
レヴォリューション・メディスンズ,インコーポレイテッド |
Ras阻害剤への獲得耐性を遅延させる、防止する、及び、治療する方法
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
EP4172323A1
(en)
|
2020-06-29 |
2023-05-03 |
Flagship Pioneering Innovations V, Inc. |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
KR20230044480A
(ko)
|
2020-07-30 |
2023-04-04 |
카이메라 쎄라퓨틱스 인코포레이티드 |
돌연변이 림프종의 치료 방법
|
JP2023536164A
(ja)
|
2020-08-03 |
2023-08-23 |
ノバルティス アーゲー |
ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
|
AU2021325225A1
(en)
|
2020-08-10 |
2023-03-23 |
Gv20 Therapeutics Llc |
Compositions and methods for treating autoimmune diseases and cancers by targeting IGSF8
|
MX2023001588A
(es)
|
2020-08-17 |
2023-05-03 |
Bicycletx Ltd |
Conjugados biciclo específicos para nectina-4 y usos de estos.
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
KR20230061430A
(ko)
|
2020-08-31 |
2023-05-08 |
브리스톨-마이어스 스큅 컴퍼니 |
세포 국재화 시그너쳐 및 면역요법
|
CN116209438A
(zh)
|
2020-09-03 |
2023-06-02 |
锐新医药公司 |
使用sos1抑制剂治疗具有shp2突变的恶性疾病
|
CA3194067A1
(en)
|
2020-09-15 |
2022-03-24 |
Revolution Medicines, Inc. |
Ras inhibitors
|
WO2022076318A1
(en)
|
2020-10-05 |
2022-04-14 |
Bristol-Myers Squibb Company |
Methods for concentrating proteins
|
US20240033358A1
(en)
|
2020-11-13 |
2024-02-01 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
CN116490607A
(zh)
|
2020-11-25 |
2023-07-25 |
上海君赛生物科技有限公司 |
肿瘤浸润淋巴细胞培养基及其应用
|
EP4252754A4
(en)
|
2020-11-25 |
2024-11-13 |
Shanghai Juncell Therapeutics Co., Ltd. |
PHARMACEUTICAL COMPOSITION FOR IMPROVING CELL KILLING AND USE THEREOF
|
KR20230131189A
(ko)
|
2020-12-02 |
2023-09-12 |
이케나 온콜로지, 인코포레이티드 |
Tead 억제제 및 이의 용도
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
CA3204091A1
(en)
|
2020-12-08 |
2022-06-16 |
Infinity Pharmaceuticals, Inc. |
Eganelisib for use in the treatment of pd-l1 negative cancer
|
JP2024501280A
(ja)
|
2020-12-22 |
2024-01-11 |
キル・レガー・セラピューティクス・インコーポレーテッド |
Sos1阻害剤およびその使用
|
ES3023507T3
(en)
|
2020-12-28 |
2025-06-02 |
Bristol Myers Squibb Co |
Antibody compositions and methods of use thereof
|
JP2024501029A
(ja)
|
2020-12-28 |
2024-01-10 |
ブリストル-マイヤーズ スクイブ カンパニー |
Pd1/pd-l1抗体の皮下投与
|
PH12023500015A1
(en)
|
2020-12-30 |
2024-03-11 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
WO2022148279A1
(zh)
*
|
2021-01-08 |
2022-07-14 |
苏州丁孚靶点生物技术有限公司 |
药物产品及其用途
|
US20250186539A2
(en)
|
2021-01-11 |
2025-06-12 |
Bicycletx Limited |
Methods for treating cancer
|
TW202246334A
(zh)
|
2021-02-02 |
2022-12-01 |
美商美國禮來大藥廠 |
Gitr拮抗劑及其使用方法
|
US12378229B2
(en)
|
2021-02-02 |
2025-08-05 |
Liminal Biosciences Limited |
GPR84 antagonists and uses thereof
|
CN117098757A
(zh)
|
2021-02-02 |
2023-11-21 |
里米诺生物科学有限公司 |
Gpr84拮抗剂和其用途
|
WO2022169921A1
(en)
|
2021-02-04 |
2022-08-11 |
Bristol-Myers Squibb Company |
Benzofuran compounds as sting agonists
|
CA3210553A1
(en)
|
2021-02-12 |
2022-08-18 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
EP4291235A4
(en)
|
2021-02-12 |
2025-01-08 |
Nimbus Saturn, Inc. |
HPK1 ANTAGONISTS AND USES THEREOF
|
CA3207049A1
(en)
|
2021-02-15 |
2022-08-18 |
Jared Gollob |
Irak4 degraders and uses thereof
|
KR20230145446A
(ko)
|
2021-02-15 |
2023-10-17 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak4 분해제 및 이의 용도
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
EP4301756A4
(en)
|
2021-03-05 |
2025-02-26 |
Nimbus Saturn, Inc. |
HPK1 ANTAGONISTS AND THEIR USES
|
US20240199648A1
(en)
|
2021-03-08 |
2024-06-20 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
EP4313989A4
(en)
|
2021-03-29 |
2025-03-05 |
Nimbus Saturn, Inc. |
HPK1 ANTAGONISTS AND USES THEREOF
|
WO2022212784A1
(en)
|
2021-03-31 |
2022-10-06 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型cdcp1に対する抗体およびその使用
|
WO2022216573A1
(en)
|
2021-04-05 |
2022-10-13 |
Bristol-Myers Squibb Company |
Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
|
FI4320112T3
(fi)
|
2021-04-06 |
2025-07-25 |
Bristol Myers Squibb Co |
Pyridinyylisubstituoituja oksoisoindoliiniyhdisteitä
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
US12325697B2
(en)
|
2021-04-09 |
2025-06-10 |
Nimbus Clio, Inc. |
CBL-B modulators and uses thereof
|
CA3215081A1
(en)
|
2021-04-16 |
2022-10-20 |
Alfredo C. Castro |
Mek inhibitors and uses thereof
|
CN117500811A
(zh)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
共价ras抑制剂及其用途
|
CN118234731A
(zh)
|
2021-05-05 |
2024-06-21 |
锐新医药公司 |
Ras抑制剂
|
CN117616031A
(zh)
|
2021-05-05 |
2024-02-27 |
锐新医药公司 |
用于治疗癌症的ras抑制剂
|
US12097261B2
(en)
|
2021-05-07 |
2024-09-24 |
Kymera Therapeutics, Inc. |
CDK2 degraders and uses thereof
|
JP7671092B2
(ja)
*
|
2021-05-10 |
2025-05-01 |
メディマブバイオ インコーポレイテッド |
抗gitr抗体およびその用途
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
WO2022246179A1
(en)
|
2021-05-21 |
2022-11-24 |
Arcus Biosciences, Inc. |
Axl inhibitor compounds
|
EP4341261A1
(en)
|
2021-05-21 |
2024-03-27 |
Arcus Biosciences, Inc. |
Axl compounds
|
WO2022254337A1
(en)
|
2021-06-01 |
2022-12-08 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
KR20240049794A
(ko)
|
2021-06-07 |
2024-04-17 |
프로비던스 헬스 앤드 서비시즈 - 오레곤 |
Cxcr5, pd-1, 및 icos 발현 종양 반응성 cd4 t 세포 및 그의 용도
|
AU2022303363A1
(en)
|
2021-06-29 |
2024-01-18 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
EP4370523A1
(en)
|
2021-07-14 |
2024-05-22 |
Blueprint Medicines Corporation |
Heterocyclic compounds as map4k1 inhibitors
|
WO2023028238A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
IL310924A
(en)
|
2021-08-25 |
2024-04-01 |
Pic Therapeutics Inc |
Eif4e inhibitors and uses thereof
|
WO2023039089A1
(en)
|
2021-09-08 |
2023-03-16 |
Twentyeight-Seven, Inc. |
Papd5 and/or papd7 inhibiting 4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivatives
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
CA3236553A1
(en)
|
2021-10-29 |
2023-05-04 |
Joel Worley BEATTY |
Inhibitors of hif-2alpha and methods of use thereof
|
CN118302168A
(zh)
|
2021-10-29 |
2024-07-05 |
凯麦拉医疗公司 |
Irak4降解剂和其制备
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023122778A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Pyridazinone derivatives useful as t cell activators
|
WO2023122777A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
WO2023122772A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
US12091411B2
(en)
|
2022-01-31 |
2024-09-17 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
EP4472963A1
(en)
|
2022-02-01 |
2024-12-11 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4479388A1
(en)
|
2022-02-14 |
2024-12-25 |
Gilead Sciences, Inc. |
Antiviral naphthyridinone compounds
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
KR20240156411A
(ko)
|
2022-03-09 |
2024-10-29 |
브리스톨-마이어스 스큅 컴퍼니 |
치료 단백질의 일시적 발현
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
CR20240379A
(es)
|
2022-03-15 |
2024-12-11 |
Compugen Ltd |
Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia combinada en el tratamiento del cáncer
|
CN118946582A
(zh)
|
2022-03-15 |
2024-11-12 |
耶达研究及发展有限公司 |
抗糖皮质激素诱导的tnfr相关(gitr)蛋白抗体及其用途
|
WO2023178329A1
(en)
|
2022-03-18 |
2023-09-21 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
WO2023215719A1
(en)
|
2022-05-02 |
2023-11-09 |
Arcus Biosciences, Inc. |
Anti-tigit antibodies and uses of the same
|
WO2023215560A1
(en)
|
2022-05-05 |
2023-11-09 |
Atoosa Corporation |
Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
|
AU2023276599A1
(en)
|
2022-05-25 |
2024-12-05 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
CN119562830A
(zh)
|
2022-06-02 |
2025-03-04 |
百时美施贵宝公司 |
抗体组合物及其使用方法
|
KR20250022133A
(ko)
|
2022-06-10 |
2025-02-14 |
레볼루션 메디슨즈, 인크. |
거대고리 ras 억제제
|
JP2025521543A
(ja)
|
2022-06-22 |
2025-07-10 |
ジュノー セラピューティクス インコーポレイテッド |
Cd19標的car t細胞のセカンドライン治療のための処置方法
|
EP4554680A1
(en)
|
2022-07-15 |
2025-05-21 |
Arcus Biosciences, Inc. |
Inhibitors of hpk1 and methods of use thereof
|
WO2024020034A1
(en)
|
2022-07-20 |
2024-01-25 |
Arcus Biosciences, Inc. |
Cbl-b inhibitors and methods of use thereof
|
IL318575A
(en)
|
2022-08-02 |
2025-03-01 |
Liminal Biosciences Ltd |
HETEROARYL CARBOXAMIDE AND GPR84-RELATED ANTAGONISTS AND USES THEREOF
|
IL318577A
(en)
|
2022-08-02 |
2025-03-01 |
Liminal Biosciences Ltd |
ARYL-TRIAZOLYL AND RELATED GPR84 ANTAGONISTS AND THEIR USES
|
EP4565564A1
(en)
|
2022-08-02 |
2025-06-11 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
US20240041929A1
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
KR20250046309A
(ko)
|
2022-08-08 |
2025-04-02 |
브리스톨-마이어스 스큅 컴퍼니 |
T 세포 활성화제로서 유용한 치환된 테트라졸릴 화합물
|
KR20250046310A
(ko)
|
2022-08-09 |
2025-04-02 |
브리스톨-마이어스 스큅 컴퍼니 |
T 세포 활성화제로서 유용한 3급 아민 치환된 비시클릭 화합물
|
CN119768401A
(zh)
|
2022-08-11 |
2025-04-04 |
豪夫迈·罗氏有限公司 |
双环四氢硫氮杂䓬衍生物
|
AR130167A1
(es)
|
2022-08-11 |
2024-11-13 |
Hoffmann La Roche |
Derivados bicíclicos de tetrahidroazepina
|
IL316935A
(en)
|
2022-08-11 |
2025-01-01 |
Hoffmann La Roche |
TETRAHYDROTHIAZEPINE DERIVATIVES CYCLES
|
AU2023322637A1
(en)
|
2022-08-11 |
2024-11-14 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024059142A1
(en)
|
2022-09-14 |
2024-03-21 |
Arcus Biosciences, Inc. |
Dispersions of etrumadenant
|
US20240174732A1
(en)
|
2022-10-05 |
2024-05-30 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
|
EP4602041A1
(en)
|
2022-10-14 |
2025-08-20 |
Arcus Biosciences, Inc. |
Hpk1 inhibitors and methods of use thereof
|
CR20250141A
(es)
|
2022-10-14 |
2025-05-26 |
Black Diamond Therapeutics Inc |
Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina
|
KR20250080902A
(ko)
|
2022-10-20 |
2025-06-05 |
아르커스 바이오사이언시즈 인코포레이티드 |
Cd73 화합물의 동결건조된 제형
|
AR131141A1
(es)
|
2022-11-22 |
2025-02-19 |
Pic Therapeutics Inc |
Inhibidores de eif4e y usos de los mismos
|
AR131320A1
(es)
|
2022-12-13 |
2025-03-05 |
Juno Therapeutics Inc |
Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos
|
WO2024137865A1
(en)
|
2022-12-22 |
2024-06-27 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
WO2024206858A1
(en)
|
2023-03-30 |
2024-10-03 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
AR132338A1
(es)
|
2023-04-07 |
2025-06-18 |
Revolution Medicines Inc |
Inhibidores de ras
|
TW202446388A
(zh)
|
2023-04-14 |
2024-12-01 |
美商銳新醫藥公司 |
Ras抑制劑之結晶形式、含有其之組合物及其使用方法
|
US20240352038A1
(en)
|
2023-04-14 |
2024-10-24 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ras相關疾病或病症之組合療法
|
US20240425497A1
(en)
|
2023-05-05 |
2024-12-26 |
Arcus Biosciences, Inc. |
Cbl-b Inhibitors and Methods of Use Thereof
|
KR20250019700A
(ko)
|
2023-05-08 |
2025-02-10 |
브리스톨-마이어스 스큅 컴퍼니 |
치환된 페닐 옥사졸론 화합물
|
US20250011318A1
(en)
|
2023-05-25 |
2025-01-09 |
Arcus Biosciences, Inc. |
Cbl-b inhibitors and methods of use thereof
|
WO2024254227A1
(en)
|
2023-06-07 |
2024-12-12 |
Bristol-Myers Squibb Company |
Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
|
EP4615455A2
(en)
|
2023-06-23 |
2025-09-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
WO2024263853A1
(en)
|
2023-06-23 |
2024-12-26 |
Bristol-Myers Squibb Company |
Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Il—18bp拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|
WO2025030002A2
(en)
|
2023-08-02 |
2025-02-06 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
WO2025034702A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Rmc-6291 for use in the treatment of ras protein-related disease or disorder
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
TW202525802A
(zh)
|
2023-09-02 |
2025-07-01 |
美商必治妥美雅史谷比公司 |
經取代之苯基氧代㗁唑基哌啶二酮化合物
|
WO2025064197A1
(en)
|
2023-09-02 |
2025-03-27 |
Bristol-Myers Squibb Company |
Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
|
WO2025054339A1
(en)
|
2023-09-08 |
2025-03-13 |
Arcus Biosciences, Inc. |
Triazolopyridine compounds as inhibitors of kit
|
US20250084056A1
(en)
|
2023-09-13 |
2025-03-13 |
Bristol-Myers Squibb Company |
Substituted oxoisoindolinyl piperidine-2,6-dione compounds
|
WO2025072330A1
(en)
|
2023-09-26 |
2025-04-03 |
Arcus Biosciences, Inc. |
Kit inhibitor compounds and methods of use thereof
|
WO2025076299A1
(en)
|
2023-10-06 |
2025-04-10 |
Arcus Biosciences, Inc. |
Cbl-b inhibitors and methods of use thereof
|
WO2025080946A2
(en)
|
2023-10-12 |
2025-04-17 |
Revolution Medicines, Inc. |
Ras inhibitors
|
WO2025096489A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
WO2025096490A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
WO2025096487A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
WO2025096494A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
WO2025096505A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
US20250145590A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
WO2025096488A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
WO2025096979A1
(en)
|
2023-11-02 |
2025-05-08 |
Arcus Biosciences, Inc. |
Thiazole compounds as kit inhibitors and methods of use thereof
|
US20250230173A1
(en)
|
2023-12-20 |
2025-07-17 |
Arcus Biosciences, Inc. |
Salt forms of an axl inhibitor
|
WO2025137507A1
(en)
|
2023-12-22 |
2025-06-26 |
Regor Pharmaceuticals, Inc. |
Sos1 inhibitors and uses thereof
|
WO2025145207A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg-depleting agent
|
WO2025193759A1
(en)
|
2024-03-12 |
2025-09-18 |
Gilead Sciences, Inc. |
Solid forms of an azolopyrimidine compound
|